|
Henderson Morley plc (“Henderson Morley” or “the Company”)
announces that the Board has, today, issued and allotted,
conditional upon Admission, a total of 30 million new
Ordinary shares through a Placing to investors at a price
of 2p per share, raising £600,000 for the Company. The
total number of shares in issue is now 491,928,631.
The purpose of this Placing is to provide the Company with
working capital to continue to invest in its ongoing
scientific programme. In this respect, the Company is
pleased to announce that three new scientists have joined
its research facility at Birmingham. These new
appointments will be focussing on the development of the
PREPS vaccine technology as a cancer immunotherapeutic;
and the further development of the vaccine candidates for
the prevention of Koi herpes.
Henderson Morley anticipates being in a position to update
shareholders shortly on the progress being made in respect
of the Koi herpes vaccine currently being undertaken at
the University of Idaho, USA.
Application will be made for the new shares to be admitted
to AIM and trading in the new shares is expected to
commence as soon as practicable.
|
